Premium
Generic Suboxone film on the horizon in the U.S.
Publication year - 2017
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30247
Subject(s) - outrage , (+) naloxone , buprenorphine , appeal , advertising , medicine , law , political science , opioid , business , receptor , politics
Last month's news that a Delaware court is allowing Dr. Reddy's, a huge supplier of generic drugs based in India, to produce a generic version of buprenorphine‐naloxone film resulted in an immediate response from Indivior, which makes Suboxone (buprenorphine‐naloxone film) and has enjoyed a monopoly on it. Reckitt Benckiser (which Indivior spun off from in 2014) aroused outrage in the treatment field when generic versions of its Suboxone tablet came on the market and it responded by pulling the tablets, making only its patented film available. Now, Indivior will appeal the court ruling.